Press Release | Dynamic42 launches Tumor Microenvironment Kit to advance complex in vitro cancer research
Jena, November 26, 2025 Dynamic42 GmbH, a biotech company based in Jena, Germany, announces the market launch of its Tumor Microenvironment (TME) Kit. The new product enables the creation of perfused 3D tumor models that reproduce the complexity of the human tumor microenvironment.
Used with the company’s DynamicOrgan® 3-Channel System, the kit supports microvasculature formation around tumor spheroids, continuous perfusion with nutrients and oxygen, and vascular drug application, bringing preclinical cancer research closer to human physiology.
Conventional 2D cultures miss essential features of solid tumors, while animal models often lack human translatability. The TME Kit bridges this gap by enabling co-culture of tumor cells with stromal, endothelial and immune cells within a 3D Matrix. Generation of a perfusable microvascular network around the tumor further allows immune cells to circulate and infiltrate the tumor tissue. This setup helps interrogate drug response, immune cell behavior, and TME-driven modulation under conditions that better reflect in vivo biology.
“The Tumor Microenvironment Kit is a milestone both for Dynamic42 and for cancer-on-chip research,” says Dr. Thomas Sommermann, head of cancer at Dynamic42. “By providing standardized, easy-to-use way to build vascularized 3D tumor models, we help researchers generate more predictive preclinical data and speed up the translation of novel cancer therapies. Strategically, the kit also marks Dynamic42’s entry into reagents, complementing our hardware-based DynamicOrgan® platform.”
The TME Kit provides all reagents and accessories needed to generate a stable, bubble-free extracellular matrix inside Dynamic42’s 3-channel biochip, in which tumor spheroids or single tumor cells can grow and interact with endothelial and immune cells. Under perfusion with growth factors, endothelial cells create a microvasculature connecting the tumor compartment to upper and lower vascular channels. This realistic setup allows for accurate drug dosing across the endothelial barrier and facilitates immune cell infiltration and polarization studies. The dynamic mechanical cues of flow further shape the TME and can reveal cellular responses not observed in static culture.
The DynamicOrgan® 3-Channel System integrates seamlessly into standard cell culture environments and supports perfusion via peristaltic pumps; laboratories with existing pumps can use the 3-Channel Kit directly. This open, modular approach gives teams flexibility to scale tissue complexity without additional capital investment, offering an accessible route to advanced cancer-on-chip research.
About Dynamic42
Dynamic42 GmbH was founded in 2018 and is a spin-off from the Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) of the University Hospital Jena. Dynamic42 markets and develops human organ-on-chip models/ microphysiological systems with integrated immune system components for research and testing of pharmaceutical products, novel therapies such as nanoparticles, chemical and food additives.
Media Contact:
Dr. Juliane Fischer
PR Management
Dynamic 42 GmbH
Winzerlaer Straße 2
07745 Jena
Phone +49 3641 508101